Treatment of Lyme Arthritis: Are DMARDs Appropriate?

The decision to use DMARD therapy in Lyme arthritis depends on whether persistent infection has been adequately treated or excluded.

The treatment of Lyme arthritis with disease-modifying antirheumatic drugs (DMARDs) remains controversial. DMARDs are designed to slow inflammatory disease progression, but their role in Lyme arthritis depends on whether symptoms reflect persistent infection or a post-infectious immune response.

Synthetic DMARDs include methotrexate and sulfasalazine. Biologic agents include tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab (Remicade®), interleukin-1 blockers such as anakinra (Kineret®), B-cell–targeting monoclonal antibodies such as rituximab, and T-cell costimulation blockers such as abatacept (Orencia®).

This clinical question reflects the broader challenge discussed in Why Lyme Disease Tests the Limits of Medicine, where symptoms, testing, and treatment response do not always align.

This question overlaps with persistent Lyme disease, where symptoms may reflect ongoing infection, immune dysregulation, or both.

Coinfections such as Babesia may also contribute to persistent symptoms and should be considered in complex cases.

These challenges are also reflected in Lyme disease testing, where results may not fully capture clinical illness.

---

A Clinical Dilemma in Lyme Arthritis Treatment

I agree with the clinical dilemma raised by Dr. Steere in the Journal of Rheumatology:

• Do patients with Lyme arthritis who fail oral antibiotics still have active B. burgdorferi infection requiring IV therapy?
• Do they have post-infectious Lyme arthritis requiring DMARD treatment?
• Or do they have another form of chronic inflammatory arthritis?

The choice matters. As Steere notes, “Either IV antibiotics or DMARD, given inappropriately, might be harmful.”

---

Persistent Infection vs Immune-Mediated Disease

I do not agree that persistent Lyme arthritis can always be explained as a post-infectious process. In some patients, the possibility of ongoing infection remains clinically relevant.

I also question the routine use of DMARDs—such as hydroxychloroquine, methotrexate, or TNF inhibitors—as a default approach for persistent Lyme arthritis.

[bctt tweet=”The evidence supporting DMARD use in Lyme arthritis remains limited and controversial.” username=”DrDanielCameron”]

---

Risks of Treatment Decisions

Both treatment strategies carry risks.

Antibiotic therapy may lead to:

• Adverse effects (e.g., C. difficile infection)
• Antibiotic resistance
• Delay in initiating alternative therapies

DMARD therapy may:

• Suppress immune response in the presence of persistent infection
• Delay appropriate antimicrobial treatment
• Lead to incomplete resolution of infection-related symptoms

The central risk is treating infection as inflammation—or inflammation as infection—without sufficient clinical certainty.

---

Evidence for DMARD Use

The evidence supporting DMARD use in Lyme arthritis is limited. Much of the data comes from case series rather than randomized clinical trials.

In one series, Arvikar and colleagues described 30 patients who developed systemic autoimmune joint disease following Lyme disease.²

• 15 had rheumatoid arthritis
• 13 had psoriatic arthritis
• 2 had peripheral spondyloarthropathy

While DMARD therapy reduced joint pain in these patients, the study did not address whether these treatments improved other common Lyme-related symptoms such as fatigue, neuropathy, neuropsychiatric symptoms, or encephalopathy.

---

Clinical Perspective

Before initiating DMARD therapy, clinicians should consider whether persistent infection has been adequately treated or ruled out.

The distinction between infection and immune-mediated disease is not always clear.

Shared decision-making is essential. Patients should be informed of the risks and uncertainties associated with both antibiotic and immunosuppressive therapies.

Careful clinical judgment, individualized treatment decisions, and ongoing reassessment remain essential in managing Lyme arthritis.

---

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention